株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

関節内補充療法:医療機器のパイプライン評価

Viscosupplementation Devices - Medical Devices Pipeline Assessment, 2019

発行 GlobalData 商品コード 512751
出版日 ページ情報 英文 83 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.67円で換算しております。
Back to Top
関節内補充療法:医療機器のパイプライン評価 Viscosupplementation Devices - Medical Devices Pipeline Assessment, 2019
出版日: 2019年10月11日 ページ情報: 英文 83 Pages
概要

当レポートでは、世界の関節内補充療法の市場における、主要なパイプライン製品 (医療機器) とその治験の進行状況について調査すると共に、製品の機能・特性の比較分析 (治験の進行段階別) や、主要企業のプロファイルおよび代表的製品、昨今の市場動静 (業績報告・資本取引動向など) といった情報を取りまとめてお届けいたします。

第1章 目次

第2章 イントロダクション

  • 関節内補充療法の概要

第3章 治験中の製品

  • パイプライン製品:治験段階別
  • パイプライン製品:セグメント別
  • パイプライン製品:地域別
  • パイプライン製品:規制経路別
  • パイプライン製品:推定認証時期別
  • 現在進行中の治験

第4章 治験中のパイプライン製品:企業別

  • 関節内補充療法の企業:治験段階別のパイプライン製品
  • 関節内補充療法:治験段階別のパイプライン製品

第5章 関節内補充療法市場:企業・製品の概要

  • Ampio Pharmaceuticals Inc
    • パイプライン製品および進行中の治験の概要
  • Anika Therapeutics Inc
  • BioTime Inc
  • Bioventus LLC
  • Carticept Medical, Inc.
  • Chi2Gel Ltd.
  • Cocoon Biotech, Inc.
  • DePuy Synthes Inc
  • Flex Biomedical Inc
  • Hanmi Pharmaceuticals
  • Kalvista Pharmaceuticals Inc
  • Moebius Medical Ltd
  • OPKO Health Inc
  • Shanghai Haohai Biological Technology Co Ltd
  • Spring Therapeutics
  • Synolyne Pharma
  • University of Kansas

第6章 関節内補充療法市場:昨今の動向 (全43件)

第7章 付録

図表

図表

List of Tables

  • Table 1: Viscosupplementation Devices - Pipeline Products by Stage of Development 7
  • Table 2: Viscosupplementation Devices - Pipeline Products by Segment 8
  • Table 3: Viscosupplementation Devices - Pipeline Products by Territory 9
  • Table 4: Viscosupplementation Devices - Pipeline Products by Regulatory Path 10
  • Table 5: Viscosupplementation Devices - Pipeline Products by Estimated Approval Date 11
  • Table 6: Viscosupplementation Devices - Ongoing Clinical Trials 12
  • Table 7: Viscosupplementation Devices Companies - Pipeline Products by Stage of Development 13
  • Table 8: Viscosupplementation Devices - Pipeline Products by Stage of Development 14
  • Table 9: Ampio Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview 15
  • Table 10: Ampion - Product Status 15
  • Table 11: Ampion - Product Description 15
  • Table 12: Ampion - Hand Osteoarthritis - Product Status 16
  • Table 13: Ampion - Hand Osteoarthritis - Product Description 16
  • Table 14: Ampio Pharmaceuticals Inc - Ongoing Clinical Trials Overview 17
  • Table 15: Ampion - A Randomized, Controlled, Double-blind Study to Evaluate the Efficacy and Safety of an Intra-articular Injection of Ampion in Adults with Pain Due to Severe Osteoarthritis of the Knee 18
  • Table 16: Anika Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 19
  • Table 17: Cingal - Product Status 19
  • Table 18: Cingal - Product Description 20
  • Table 19: Hyaluronic Acid - Synovial Joints - Product Status 20
  • Table 20: Hyaluronic Acid - Synovial Joints - Product Description 20
  • Table 21: MONOVISC - Hip - Product Status 21
  • Table 22: MONOVISC - Hip - Product Description 21
  • Table 23: ORTHOVISC-T - Product Status 21
  • Table 24: ORTHOVISC-T - Product Description 22
  • Table 25: Anika Therapeutics Inc - Ongoing Clinical Trials Overview 23
  • Table 26: Cingal - A Prospective Evaluation of the Cingal Injection for Hip Osteoarthritis (ECHO Study) 24
  • Table 27: MONOVISC - Hip - Investigational Device Exemption (IDE) Phase III Study of MONOVISC to Treat Pain Caused by Osteoarthritis of the Hip 25
  • Table 28: ORTHOVISC-T - A Prospective, Open-label, Multi-center Post-market Clinical Follow-up Study to Evaluate the Residual Risk of OrthoVisc-T (OVT) in the Treatment of Chronic Lateral Epicondylosis (Tennis Elbow) 26
  • Table 29: Carticept Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 27
  • Table 30: Agilus - Product Status 27
  • Table 31: Agilus - Product Description 27
  • Table 32: Chi2Gel Ltd. Pipeline Products & Ongoing Clinical Trials Overview 28
  • Table 33: Chi2Knee - Product Status 28
  • Table 34: Chi2Knee - Product Description 28
  • Table 35: Cocoon Biotech, Inc. Pipeline Products & Ongoing Clinical Trials Overview 29
  • Table 36: Silk Hydrogel - Product Status 29
  • Table 37: Silk Hydrogel - Product Description 29
  • Table 38: Flex Biomedical Inc Pipeline Products & Ongoing Clinical Trials Overview 30
  • Table 39: Flex Polymer - Product Status 30
  • Table 40: Flex Polymer - Product Description 30
  • Table 41: Herng Shan Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 31
  • Table 42: Hyalease 16 - Product Status 31
  • Table 43: Hyalease 16 - Product Description 31
  • Table 44: Hyalease 20 - Product Status 32
  • Table 45: Hyalease 20 - Product Description 32
  • Table 46: Hyalease 8 - Product Status 32
  • Table 47: Hyalease 8 - Product Description 32
  • Table 48: Kalvista Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview 33
  • Table 49: ActaVisc - Product Status 33
  • Table 50: ActaVisc - Product Description 33
  • Table 51: Hydros - Product Status 34
  • Table 52: Hydros - Product Description 34
  • Table 53: Hydros TA - Product Status 34
  • Table 54: Hydros TA - Product Description 35
  • Table 55: Hydros TA - Hip - Product Status 35
  • Table 56: Hydros TA - Hip - Product Description 35
  • Table 57: KiOmed Pharma Pipeline Products & Ongoing Clinical Trials Overview 36
  • Table 58: Arthrovisc - Product Status 36
  • Table 59: Arthrovisc - Product Description 36
  • Table 60: Lineage Cell Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 37
  • Table 61: ReGlyde - Product Status 37
  • Table 62: ReGlyde - Product Description 37
  • Table 63: Medytox Inc Pipeline Products & Ongoing Clinical Trials Overview 38
  • Table 64: MT941 - Product Status 38
  • Table 65: MT941 - Product Description 38
  • Table 66: Moebius Medical Ltd Pipeline Products & Ongoing Clinical Trials Overview 39
  • Table 67: MM-II - Product Status 39
  • Table 68: MM-II - Product Description 39
  • Table 69: OPKO Health Inc Pipeline Products & Ongoing Clinical Trials Overview 40
  • Table 70: Enko 1 - Product Status 40
  • Table 71: Enko 1 - Product Description 40
  • Table 72: Shin Poong Pharm Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 41
  • Table 73: HyalOne - Product Status 41
  • Table 74: HyalOne - Product Description 41
  • Table 75: University of Kansas Pipeline Products & Ongoing Clinical Trials Overview 42
  • Table 76: 3-D Colloidal Gel - Product Status 42
  • Table 77: 3-D Colloidal Gel - Product Description 42
  • Table 78: Glossary 82

List of Figures

  • Figure 1: Viscosupplementation Devices - Pipeline Products by Stage of Development 7
  • Figure 2: Viscosupplementation Devices - Pipeline Products by Segment 8
  • Figure 3: Viscosupplementation Devices - Pipeline Products by Territory 9
  • Figure 4: Viscosupplementation Devices - Pipeline Products by Regulatory Path 10
  • Figure 5: Viscosupplementation Devices - Pipeline Products by Estimated Approval Date 11
  • Figure 6: Viscosupplementation Devices - Ongoing Clinical Trials 12
目次
Product Code: GDME0795EPD

GlobalData's Medical Devices sector report, "Viscosupplementation Devices - Medical Devices Pipeline Assessment, 2019" provides an overview of Viscosupplementation Devices currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Viscosupplementation Devices pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Viscosupplementation Devices under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Viscosupplementation Devices and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to buy

The report enables you to -

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Viscosupplementation Devices under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date

Table of Contents

1. Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2 Introduction

  • 2.1 Viscosupplementation Devices Overview

3 Products under Development

  • 3.1 Viscosupplementation Devices - Pipeline Products by Stage of Development
  • 3.2 Viscosupplementation Devices - Pipeline Products by Segment
  • 3.3 Viscosupplementation Devices - Pipeline Products by Territory
  • 3.4 Viscosupplementation Devices - Pipeline Products by Regulatory Path
  • 3.5 Viscosupplementation Devices - Pipeline Products by Estimated Approval Date
  • 3.6 Viscosupplementation Devices - Ongoing Clinical Trials

4 Viscosupplementation Devices - Pipeline Products under Development by Companies

  • 4.1 Viscosupplementation Devices Companies - Pipeline Products by Stage of Development
  • 4.2 Viscosupplementation Devices - Pipeline Products by Stage of Development

5 Viscosupplementation Devices Companies and Product Overview

  • 5.1 Ampio Pharmaceuticals Inc Company Overview
  • 5.2 Anika Therapeutics Inc Company Overview
  • 5.3 Carticept Medical Inc Company Overview
  • 5.4 Chi2Gel Ltd. Company Overview
  • 5.5 Cocoon Biotech, Inc. Company Overview
  • 5.6 Flex Biomedical Inc Company Overview
  • 5.7 Herng Shan Co Ltd Company Overview
  • 5.8 Kalvista Pharmaceuticals Inc Company Overview
  • 5.9 KiOmed Pharma Company Overview
  • 5.10 Lineage Cell Therapeutics Inc Company Overview
  • 5.11 Medytox Inc Company Overview
  • 5.12 Moebius Medical Ltd Company Overview
  • 5.13 OPKO Health Inc Company Overview
  • 5.14 Shin Poong Pharm Co Ltd Company Overview
  • 5.15 University of Kansas Company Overview

6 Viscosupplementation Devices - Recent Developments

  • 6.1 Sep 09, 2019: Bioventus agrees to nationwide contract with UnitedHealthcare commercial plans
  • 6.2 Sep 09, 2019: KalVista Pharmaceuticals reports fiscal first quarter results
  • 6.3 Aug 22, 2019: Ampio Pharmaceuticals retains financial advisor and appoints Transaction Advisory Committee
  • 6.4 Aug 12, 2019: Bioventus launches DUROLANE SJ (1mL) in Australia and New Zealand; receives expanded indications for DUROLANE (3mL)
  • 6.5 Jul 31, 2019: Smith & Nephew second quarter and first half 2019 results
  • 6.6 Jul 24, 2019: Anika reports second quarter 2019 financial results
  • 6.7 Jul 17, 2019: OrthogenRx CEO awarded 2019 Entrepreneur of the Year
  • 6.8 Jul 08, 2019: Anika appoints James Loerop as executive vice president of business development and strategic planning
  • 6.9 May 21, 2019: New U.S. Patents granted for RegenLab
  • 6.10 May 13, 2019: Anika to showcase regenerative medicine and orthobiologics portfolio at the 12th Biennial International Society of Arthroscopy, Knee Surgery and Orthopaedic Sports Medicine Congress
  • 6.11 May 07, 2019: Smith & Nephew: Change of registered office
  • 6.12 May 02, 2019: Smith & Nephew first quarter 2019 trading report
  • 6.13 May 02, 2019: Anika reports first quarter 2019 financial results
  • 6.14 Apr 30, 2019: Anika Therapeutics names Stephen Goldy as vice president of U.S. Sales
  • 6.15 Apr 22, 2019: KalVista Pharmaceuticals names Daniel B. Soland to board of directors
  • 6.16 Apr 03, 2019: Anika to highlight regenerative medicine and Orthobiologics Portfolio at 2019 Asia Pacific Orthopaedic Association Sports Meeting
  • 6.17 Mar 29, 2019: PolarityTE announces Richard Hague, formerly from Sanofi, Genzyme and recently Anika Therapeutics as Chief Operating Officer
  • 6.18 Mar 25, 2019: Smith & Nephew: Re-presented historical quarterly revenue analysis
  • 6.19 Mar 22, 2019: Seikagaku launches HyLink, an intra-articular single-injection viscosupplement for the treatment of knee osteoarthritis in Italy
  • 6.20 Mar 18, 2019: Anika Therapeutics names Robert Richard as Vice President of research and development
  • 6.21 Mar 14, 2019: Kalvista Pharmaceuticals reports fiscal third quarter result
  • 6.22 Mar 06, 2019: Ampio updates regulatory status for Ampion
  • 6.23 Feb 21, 2019: Anika reports fourth quarter and full year 2018 financial results
  • 6.24 Feb 20, 2019: Smith & Nephew celebrates 18th year on FTSE4Good index
  • 6.25 Feb 08, 2019: Smith & Nephew: Directorate changes
  • 6.26 Feb 07, 2019: Smith & Nephew fourth quarter and full year 2018 results
  • 6.27 Feb 06, 2019: Ampio updates status of pivotal clinical trial of Ampion to be carried out under a SPA
  • 6.28 Feb 04, 2019: KYERON receives CE mark approval for
  • 6.29 Feb 01, 2019: KalVista Pharmaceuticals names Brian J. G. Pereira as Board Director
  • 6.30 Jan 29, 2019: Bioventus Launches DUROLANE in Malaysia and Selects Athrotech as Exclusive Distribution Partner
  • 6.31 Dec 14, 2018: KalVista Pharmaceuticals reports fiscal 2018 second quarter results
  • 6.32 Dec 13, 2018: Overland Park Surgical Suites first outpatient surgery center in region to offer robotics-assisted partial and total knee replacement surgery using the Navio surgical system
  • 6.33 Dec 10, 2018: StimLabs announces Department of Veterans Affairs (VA) And Department of Defense (DoD) Agreements
  • 6.34 Nov 01, 2018: Smith & Nephew third quarter 2018 trading report
  • 6.35 Oct 25, 2018: Susan M. Stalnecker named to Bioventus Board of Managers
  • 6.36 Oct 24, 2018: Anika Therapeutics announces Third Quarter 2018 Financial Results
  • 6.37 Oct 24, 2018: Anika Therapeutics names Susan Vogt as Board Director
  • 6.38 Oct 02, 2018: Bioventus Receives ANVISA Approval to Market DUROLANE in Brazil and Selects Pfizer as Exclusive Distribution Partner

7 Appendix

  • 7.1 Methodology
  • 7.2 About GlobalData
  • 7.3 Contact Us
  • 7.4 Disclaimer
Back to Top